- June 2025Lifestyles of the Rich and Famous: Fiduciary Responsibility in the Spotlight
- June 2025Your Place or Mine? How to Navigate Cross-Jurisdictional Fiduciary Litigation
- June 2025Avoiding a Tragic End to a Fiduciary Relationship
- Back in the doghouse: Parody and trademarks post-Jack Daniel's
- D. Del. May 30, 2025Astellas Pharma Inc. v. Zydus, Inc. II
- Mergers Face Steeper Slopes In State Antitrust Reviews
- What to Do When the Government Comes Knocking: Responding Strategically to Investigations, Inspections and Demands
- N.D. Ill. May 9, 2025Ingenus Pharms., LLC v. Nexus Pharms., Inc.
- Fed. Cir. May 6, 2025Jazz Pharms., Inc. v. Avadel CNS Pharms., LLC
- D.D.C. May 2, 2025Liquidia Techs., Inc. v. FDA
- Spring 2025Unraveling the Webs to Hold Online Retailers Accountable
- Fed. Cir. Apr. 23, 2025Metacel Pharms. LLC v. Rubicon Rsch. Priv. Ltd.
- What’s Good for the Goose Is Good for the Government
- March 26, 2025Mind the Gap: Steps Appellate Judges Can Take to Strengthen the Public’s Understanding of the Judiciary
- Second QuarterNew ANDA Cases
- Second QuarterANDA Litigation Settlements
- D.D.C. Apr. 18, 2025Norwich Pharms., Inc. v. Kennedy Jr.
- 2025 Bulletin - First QuarterGENERICally Speaking: A Hatch-Waxman Litigation Bulletin 2025 Q1
- Second QuarterGeneric Launches
- Second QuarterANDA Approvals
- D. Del. Feb. 5, 2025Alcon Inc. v. Padagis Israel Pharms. Ltd.
- D. Del. Jan. 10, 2025Boehringer Ingelheim Pharms. Inc. v. Apotex Inc.
- Fed. Cir. Jan. 10, 2025In re Entresto
- N.D. Ill. Feb. 27, 2025Janssen Prods., L.P. v. EVER Valinject GmbH
- (Fed. Cir. Mar. 28, 2025)Janssen Pharms., Inc. v. Mylan Labs. Ltd.
- D.D.C. Feb. 27, 2025Liquidia Techs., Inc. v. FDA
- D. Del. Feb. 12, 2025Mallinckrodt Pharms. Ireland Ltd. v. Airgas Therapeutics LLC
- Fed. Cir. Mar. 13, 2025Merck Sharp & Dohme B.V. v. Aurobindo Pharma USA, Inc
- D. Del. Jan. 23, 2025Taiho Pharma Co. v. MSN Labs Private Ltd.
- D.D.C. Feb. 13, 2025Vanda Pharms., Inc. v. FDA
- D. Del. Apr. 15, 2025Astellas Pharma Inc. v. Zydus, Inc. I
- First QuarterNew ANDA Cases
- First QuarterANDA Litigation Settlements
- First QuarterANDA Approvals
- First QuarterGeneric Launches
- Fed. Cir. Apr. 8, 2025Azurity Pharms., Inc. v. Alkem Labs. Ltd.
- The Evolving Role of Internal Corporate Investigations: Why Proactive Oversight Matters More Than Ever
- March 2025Michael Reif: Finding a New Purpose in Personal Injury Law
- March 2025Settlement Highlights Issue of Deliberate Indifference Involving Medical Need in Jails
- March 2025Navigating General and Limited Partnerships: Common Pitfalls and How to Avoid Them
- March 2025Show Me the Books! Navigating Minority Shareholder Access to Corporate Information
- January 2025Silent Dangers: The Link Between Depo-Provera, Brain Tumors, and Health Inequities
- Purdue Pharma L.P. v. Accord Healthcare, Inc.
- Teva Branded Pharm. Products R&D, Inc. v. Amneal Pharms. of NY, LLC
- December 2024Board Governance in the Age of AI: Navigating Risks of Note-Taking Tools
- December 2024Navigating AI and Fiduciary Duties: 10 Key Questions for Your Organization
- December 2024Letter from the Editor
- Janssen Pharms., Inc. v. Teva Pharms. USA, Inc.
- Galderma Labs., L.P. v. Lupin Inc.
- Novartis Pharms. Corp. v. MSN Pharms., Inc.
